Floatz logo

Samuraciclib

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

Hoffmann-La RocheSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

76 Active assets in the Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Abemaciclib
Jonsson Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Samuraciclib is also rated in:

breast cancerDormant
B
Indicative ·
61 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
Advanced Solid MalignanciesDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →